出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2024年3月
Monoclonal Antibody (mABs) Therapeutics Market – Global Forecast to 2029
モノクローナル抗体 (mAB) 治療薬市場 : 製造方法 (In-Vitro、In-Vivo)、原料 (ヒト、キメラ型)、投与経路 (静脈内、皮下)、治療法 (炎症＆自己免疫、腫瘍学、血液学) – 2029年までの世界予測
Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) – Global Forecast to 2029
| ページ数 | 351 |
| 図表数 | 423 |
| 価格 | |
| シングルユーザライセンス | USD 4,950 |
| マルチユーザライセンス（5名） | USD 6,650 |
| コーポレート（サイト）ライセンス | USD 8,150 |
| エンタープライズライセンス | USD 10,000 |
| 種別 | 英文調査報告書 |
Report Overview
The monoclonal antibody therapeutics market is projected to reach USD 497.5 billion by 2029 from an estimated USD 252.6 billion in 2024, at a CAGR of 14.5% during the forecast period.
モノクローナル抗体 (mAB) 治療薬市場は、2024年の推定2,526億米ドルから2029年までに4,975億米ドルに達すると予測されており、予測期間中のCAGRは14.5%です。
The driving factors of the monoclonal antibody therapeutics market include increased prevalence of chronic diseases, advancements in biotechnology, and growing demand for targeted therapies. Examples include drugs like Rituxan (rituximab) for lymphoma, Humira (adalimumab) for autoimmune disorders, and Keytruda (pembrolizumab) for cancer immunotherapy, driving market growth through their effectiveness and broad applications.
“The In-Vitro segment accounted for the largest share by production method in 2023.”
Based on production method, the monoclonal antibody therapeutics market is segmented into in-vitro and in-vivo. In 2023, in-vitro segment dominated the monoclonal antibody therapeutics market. Driving factors of the in-vitro production method monoclonal antibody therapeutics market include scalability, cost-effectiveness, reduced batch-to-batch variability, and regulatory compliance, meeting demand for reliable and consistent biopharmaceutical production.
“The human segment accounted for the largest share by source in 2023.”
Based on source, the monoclonal antibody therapeutics market is segmented into human, humanized, chimeric and other sources. In 2023, human source segment dominated market and humanized segment is likely to grow at significant CAGR during the forecast period. The driving factors of the human source monoclonal antibody therapeutics market include reduced immunogenicity, enhanced efficacy, and improved safety profiles compared to non-human sources. Additionally, advancements in humanization techniques and increased understanding of human immune responses contribute to the growth of this market, catering to diverse therapeutic needs.
“The autoimmune & inflammatory disease segment accounted for the largest share by therapy area in 2023.”
The monoclonal antibody therapeutics market is segmented into autoimmune & inflammatory disorders, Oncology, Hematology, opthalmology and other therapy area. In 2023, autoimmune & inflammatory diseases dominated the monoclonal antibody therapeutics market. Cancer segment is anticipated to grow at significant CAGR during the forecast period of 2024-2029. The high growth cancer monoclonal antibody therapeutics is propelled by increasing incidences of cancer globally, coupled with growing acceptance of targeted therapies. Continuous research and development efforts, along with advancements in biotechnology, contribute to the robust growth trajectory of this segment.
““The Europe is growing at the highest CAGR in the monoclonal antibody therapeutics market during the forecast period of 2024-2029.”
North America dominates the monoclonal antibody therapeutics market. Europe, is likely to grow at highest CAGR owing to various factors such as favorable regulatory frameworks, robust healthcare infrastructure, increasing investment in research and development, and rising prevalence of chronic diseases. These elements collectively foster a conducive environment for market expansion and innovation.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East & Africa- 5%
List of Companies Profiled in the Report:
• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbvie Inc. (US)
• Johnson & Johnson Services, Inc. (US)
• Merck & Co., Inc. (US)
• Bristol Myers Squibb Company (US)
• AstraZeneca (UK)
• Sanofi (France)
• Novartis AG (Switzerland)
• Amgen Inc. (US)
• Takeda Pharmaceutical Company Limited (Japan)
• GSK plc. (UK)
• Eli Lilly and Company (US)
• Regeneron Pharmaceuticals Inc. (US)
• Biogen (US)
• UCB S.A. (Belgium)
• Boehringer Ingelheim International GmbH (Germany)
• Y-mAbs Therapeutics Inc. (US)
• Teva Pharmaceutical Industries Ltd. (Israel),
• Merck KGaA (Germany)
• Kyowa Kirin Co. Ltd. (Japan)
• Swedish Orphan Biovitrum AB (Sweden)
• United Therapeutics Corporation (US)
• Theratechnologies Inc. (Canada)
• Incyte (US)
• Sun Pharmaceutical Industries Ltd. (India)
Research Coverage:
This research report categorizes the monoclonal antibody therapeutics market by production method (in-vitro and in-vivo), source (human, humanized, chimeric and other sources), therapy area (autoimmune & inflammatory disorders, Oncology, Hematology, opthalmology and other therapy area), route of administration (intravenous, subcutaneous and other route of administration), end user (hospitals, long-term care facilities, and other end user) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and trends influencing the growth of the monoclonal antibody therapeutics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product/service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, acquisitions, and recent developments associated with the monoclonal antibody therapeutics market. Competitive analysis of top players and upcoming startups in the monoclonal antibody therapeutics market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall monoclonal antibody therapeutics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Advancements in biotechnology and genetic engineering, Increasing demand for personalized medicine, Growing product pipeline of innovative mAb therapeutics) restraints (Stringent regulatory approval process and High cost of mAb treatments), opportunities (Innovative therapeutic indications, Rising technological advancements in antibody engineering), and challenges (Rising production costs for mAbs) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the monoclonal antibody therapeutics market
• Clinical Trials: Detail Analysis on the products under clinical trials phase III and phase II&III.
• Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the monoclonal antibody therapeutics market
• Competitive Assessment: are F. Hoffmann-La Roche Ltd (Switzerland), Abbvie Inc. (US), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Bristol Myers Squibb Company (US), AstraZeneca (UK), Sanofi (France), Novartis AG (Switzerland), Amgen Inc. (US), Takeda Pharmaceutical Company Limited (Japan), GSK plc. (UK), Eli Lilly and Company (US), among others in the market.
Table of Contents
1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS & EXCLUSIONS 29
1.3 MARKET SCOPE 30
1.3.1 MARKETS COVERED 30
1.3.2 YEARS CONSIDERED 31
1.3.3 CURRENCY CONSIDERED 31
1.4 RESEARCH LIMITATIONS 31
1.5 STAKEHOLDERS 32
1.6 RECESSION IMPACT 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
FIGURE 1 RESEARCH DESIGN 33
2.1.1 SECONDARY DATA 34
2.1.2 PRIMARY DATA 35
FIGURE 2 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES 35
2.2 MARKET SIZE ESTIMATION 36
FIGURE 3 MONOCLONAL ANTIBODY THERAPEUTICS: MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2023 36
FIGURE 4 MONOCLONAL ANTIBODY THERAPEUTICS: MARKET SIZE ESTIMATION (PRODUCT-BASED ANALYSIS), 2023 37
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023 38
FIGURE 6 ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE AG: REVENUE SHARE ANALYSIS, 2023 38
2.2.1 INSIGHTS FROM PRIMARIES 40
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS 40
2.2.2 SEGMENT ASSESSMENT (BY PRODUCTION METHOD, SOURCE, ROUTE OF ADMINISTRATION, THERAPY AREA, AND END USER) 40
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 40
2.3 GROWTH RATE ASSUMPTIONS 41
FIGURE 9 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: CAGR PROJECTIONS, 2024–2029 42
FIGURE 10 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 42
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 43
FIGURE 11 DATA TRIANGULATION METHODOLOGY 43
2.5 STUDY ASSUMPTIONS 44
2.6 RISK ANALYSIS 44
2.7 RECESSION IMPACT ANALYSIS 45
3 EXECUTIVE SUMMARY 46
FIGURE 12 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2024 VS. 2029 (USD MILLION) 46
FIGURE 13 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION) 47
FIGURE 14 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY TYPE, 2024 VS. 2029 (USD MILLION) 47
FIGURE 15 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 48
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF MONOCLONAL ANTIBODY THERAPEUTICS MARKET 49
4 PREMIUM INSIGHTS 50
4.1 MONOCLONAL ANTIBODY THERAPEUTICS MARKET OVERVIEW 50
FIGURE 17 ADVANCEMENTS IN BIOTECHNOLOGY AND GENETIC ENGINEERING TO DRIVE MARKET DURING FORECAST PERIOD 50
4.2 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD (2023) 51
FIGURE 18 IN-VITRO PRODUCTION METHOD ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 51
4.3 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION) 51
FIGURE 19 HUMAN SOURCE SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 51
4.4 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
FIGURE 20 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
FIGURE 21 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53
5.2.1 DRIVERS 54
5.2.1.1 Advancements in biotechnology and genetic engineering 54
5.2.1.2 Increasing demand for personalized medicine 55
5.2.1.3 Growing product pipeline of mAb therapeutics 55
FIGURE 22 NUMBER OF ANTIBODY THERAPEUTICS GRANTED FIRST APPROVAL IN US/EU (2012−2023) 56
5.2.2 RESTRAINTS 56
5.2.2.1 Stringent regulatory approval process 56
5.2.2.2 High cost of mAb treatments 57
5.2.3 OPPORTUNITIES 57
5.2.3.1 Innovative therapeutic indications 57
5.2.3.2 Rising technological advancements in antibody engineering 58
5.2.4 CHALLENGES 59
5.2.4.1 Rising development & production costs 59
5.3 PORTER’S FIVE FORCES ANALYSIS 59
TABLE 1 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 59
5.3.1 THREAT OF NEW ENTRANTS 59
5.3.2 THREAT OF SUBSTITUTES 60
5.3.3 BARGAINING POWER OF SUPPLIERS 60
5.3.4 BARGAINING POWER OF BUYERS 60
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 60
5.4 TECHNOLOGY ANALYSIS 60
5.4.1 CONVENTIONAL PRODUCTION OF MABS 61
5.4.2 TECHNOLOGICAL ADVANCEMENTS FOR MABS 61
TABLE 2 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: TECHNOLOGY COMPARISON 62
5.5 VALUE CHAIN ANALYSIS 63
FIGURE 23 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: VALUE CHAIN 63
5.6 PATENT ANALYSIS 64
5.6.1 METHODOLOGY 64
5.6.2 PATENTS FILED BY DOCUMENT TYPE, 2014–2023 64
TABLE 3 PATENTS FILED, 2014–2023 64
5.6.3 INNOVATION AND PATENT APPLICATIONS 65
FIGURE 24 TOTAL NUMBER OF PATENTS GRANTED, 2014–2023 65
5.6.4 TOP APPLICANTS 65
FIGURE 25 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2023 65
FIGURE 26 REGIONAL ANALYSIS OF PATENTS GRANTED, 2014–2023 66
TABLE 4 TOP 10 PATENT OWNERS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET, 2013–2023 66
TABLE 5 PATENTS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET, 2023−2024 67
5.7 KEY CONFERENCES & EVENTS 68
TABLE 6 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2024–2025) 68
5.8 INVESTMENT AND FUNDING SCENARIO 69
5.9 PIPELINE ANALYSIS 69
TABLE 7 MONOCLONAL ANTIBODY THERAPEUTICS IN CLINICAL PIPELINE 70
5.10 SUPPLY CHAIN ANALYSIS 77
FIGURE 27 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS 78
5.11 ECOSYSTEM ANALYSIS 78
FIGURE 28 MONOCLONAL ANTIBODY THERAPEUTICS ECOSYSTEM 78
5.11.1 MONOCLONAL ANTIBODY THERAPEUTIC VENDORS 78
TABLE 8 MONOCLONAL ANTIBODY THERAPEUTIC VENDORS 79
5.11.2 END USERS OF MONOCLONAL ANTIBODY THERAPEUTICS 79
TABLE 9 MONOCLONAL ANTIBODY THERAPEUTIC END USERS 79
5.11.3 REGULATORY BODIES FOR MONOCLONAL ANTIBODY THERAPEUTICS 80
TABLE 10 MONOCLONAL ANTIBODY THERAPEUTIC REGULATORY BODIES 80
5.12 REGULATORY LANDSCAPE 80
5.12.1 REGULATORY ANALYSIS 80
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
5.13 PRICING ANALYSIS 83
5.13.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS 83
TABLE 15 AVERAGE SELLING PRICE OF MONOCLONAL ANTIBODY THERAPEUTICS IN US 83
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 83
FIGURE 29 TECHNOLOGICAL ADVANCEMENTS IN MONOCLONAL ANTIBODY PRODUCTION TO DRIVE MARKET GROWTH 84
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 85
5.15.1 KEY STAKEHOLDERS ON BUYING PROCESS 85
FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MABS AMONG TOP TWO END USERS 85
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO END USERS 85
5.15.2 BUYING CRITERIA FOR MONOCLONAL ANTIBODY THERAPEUTICS 86
FIGURE 31 KEY BUYING CRITERIA FOR HOSPITALS AND LONG-TERM CARE FACILITIES 86
TABLE 17 KEY BUYING CRITERIA FOR TOP TWO END USERS 86
6 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD 88
6.1 INTRODUCTION 89
TABLE 18 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 89
6.2 IN-VITRO PRODUCTION 89
6.2.1 HIGH SCALABILITY AND COST EFFICIENCY TO PROPEL MARKET 89
TABLE 19 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY REGION, 2022–2029 (USD MILLION) 90
TABLE 20 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 90
TABLE 21 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 91
TABLE 22 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 91
TABLE 23 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 92
TABLE 24 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY REGION, 2022–2029 (USD MILLION) 92
TABLE 25 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 92
6.3 IN-VIVO PRODUCTION 93
6.3.1 MINIMAL SIDE-EFFECTS TO SUPPORT MARKET GROWTH 93
TABLE 26 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY REGION, 2022–2029 (USD MILLION) 93
TABLE 27 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 94
TABLE 28 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 94
TABLE 29 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 95
TABLE 30 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 95
TABLE 31 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY REGION, 2022–2029 (USD MILLION) 96
TABLE 32 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 96
7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION 97
7.1 INTRODUCTION 98
TABLE 33 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 98
7.2 INTRAVENOUS ROUTE OF ADMINISTRATION 98
7.2.1 DIRECT DELIVERY OF THERAPEUTIC DOSAGE FOR MULTIPLE INDICATIONS TO DRIVE MARKET 98
TABLE 34 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION) 99
TABLE 35 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 99
TABLE 36 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 37 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 38 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 39 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION) 101
TABLE 40 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 101
7.3 SUBCUTANEOUS ROUTE OF ADMINISTRATION 102
7.3.1 ENHANCED PATIENT ADHERENCE AND LOW HEALTHCARE COSTS TO DRIVE MARKET 102
TABLE 41 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION) 103
TABLE 42 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 103
TABLE 43 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 44 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 45 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 46 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022−2029 USD MILLION) 105
TABLE 47 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 105
7.4 OTHER ROUTES OF ADMINISTRATION 106
TABLE 48 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION) 106
TABLE 49 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 50 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 51 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 52 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 53 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION) 109
TABLE 54 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTESC OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 109
8 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE 110
8.1 INTRODUCTION 111
TABLE 55 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 111
8.2 HUMAN SOURCE 111
8.2.1 REDUCED IMMUNOGENICITY AND IMPROVED EFFICACY TO PROPEL MARKET 111
TABLE 56 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY REGION, 2022–2029 (USD MILLION) 112
TABLE 57 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 58 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 59 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 60 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 61 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY REGION, 2022–2029 (USD MILLION) 114
TABLE 62 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 114
8.3 HUMANIZED SOURCE 115
8.3.1 ABILITY TO ADJUST SPECIFICITY AND BIOLOGICAL FUNCTIONS TO DRIVE MARKET 115
TABLE 63 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY REGION, 2022–2029 (USD MILLION) 115
TABLE 64 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 65 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 66 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 67 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 68 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY REGION, 2022–2029 (USD MILLION) 118
TABLE 69 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 118
8.4 CHIMERIC SOURCE 118
8.4.1 UTILIZATION OF GENETIC ENGINEERING TECHNIQUES FOR MINIMIZED IMMUNOGENIC RESPONSES TO FUEL MARKET 118
TABLE 70 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY REGION, 2022–2029 (USD MILLION) 119
TABLE 71 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 119
TABLE 72 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 73 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 74 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 121
TABLE 75 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY REGION, 2022–2029 (USD MILLION) 121
TABLE 76 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 121
8.5 OTHER SOURCES 122
TABLE 77 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY REGION, 2022–2029 (USD MILLION) 122
TABLE 78 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 79 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 80 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 81 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 82 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY REGION, 2022–2029 (USD MILLION) 125
TABLE 83 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION) 125
9 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA 126
9.1 INTRODUCTION 127
TABLE 84 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 127
9.2 INFLAMMATORY & AUTOIMMUNE DISORDERS 127
9.2.1 RISING DEMAND FOR TARGETED THERAPEUTICS TO DRIVE MARKET 127
TABLE 85 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY REGION, 2022–2029 (USD MILLION) 128
TABLE 86 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 87 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 88 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 89 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 90 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY REGION, 2022–2029 (USD MILLION) 130
TABLE 91 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 130
9.3 ONCOLOGY 131
9.3.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO PROPEL MARKET 131
TABLE 92 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION) 132
TABLE 93 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 94 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 95 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 96 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 97 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022−2029 (USD MILLION) 134
TABLE 98 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022−2029 (USD MILLION) 134
9.4 HEMATOLOGY 135
9.4.1 RISING INCIDENCE OF THROMBOTIC DISORDERS TO SUPPORT MARKET GROWTH 135
TABLE 99 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY REGION, 2022−2029 (USD MILLION) 135
TABLE 100 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 101 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022−2029 (USD MILLION) 136
TABLE 102 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 103 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 104 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY REGION, 2022–2029 (USD MILLION) 138
TABLE 105 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 138
9.5 OPHTHALMOLOGY 138
9.5.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION TO BOOST DEMAND 138
TABLE 106 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY REGION, 2022–2029 (USD MILLION) 139
TABLE 107 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 108 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 109 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 110 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 111 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY REGION, 2022–2029 (USD MILLION) 141
TABLE 112 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 141
9.6 OTHER THERAPY AREAS 142
TABLE 113 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2029 (USD MILLION) 143
TABLE 114 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 115 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 116 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 117 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 118 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2029 (USD MILLION) 145
TABLE 119 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 145
10 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER 146
10.1 INTRODUCTION 147
TABLE 120 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 147
10.2 HOSPITALS 147
10.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET 147
TABLE 121 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION) 148
TABLE 122 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 123 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 124 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 125 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 126 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION) 150
TABLE 127 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 150
10.3 LONG-TERM CARE FACILITIES 151
10.3.1 SPECIALIZED CARE AND CONTINUOUS MONITORING ADVANTAGES TO DRIVE MARKET 151
TABLE 128 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION) 151
TABLE 129 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 130 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 131 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 132 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 133 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION) 154
TABLE 134 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 154
10.4 OTHER END USERS 155
TABLE 135 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION) 155
TABLE 136 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 137 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 138 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 139 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 140 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION) 157
TABLE 141 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 157
11 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION 158
11.1 INTRODUCTION 159
TABLE 142 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 159
11.2 NORTH AMERICA 159
FIGURE 32 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET SNAPSHOT 160
TABLE 143 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 144 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 161
TABLE 145 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 162
TABLE 146 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 162
TABLE 147 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 163
TABLE 148 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 163
11.2.1 NORTH AMERICA: RECESSION IMPACT 164
11.2.2 US 164
11.2.2.1 Rising regulatory approvals for product commercialization to propel market 164
TABLE 149 PRODUCT APPROVALS FOR MAB THERAPEUTICS BY US FDA 165
TABLE 150 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 165
TABLE 151 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 166
TABLE 152 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 166
TABLE 153 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 167
TABLE 154 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 167
11.2.3 CANADA 167
11.2.3.1 Rising investments in antibody research to support market growth 167
TABLE 155 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 168
TABLE 156 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 168
TABLE 157 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 169
TABLE 158 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 169
TABLE 159 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 170
11.3 EUROPE 170
FIGURE 33 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET SNAPSHOT 171
TABLE 160 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 172
TABLE 161 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 172
TABLE 162 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 173
TABLE 163 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 173
TABLE 164 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 174
TABLE 165 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 174
11.3.1 EUROPE: RECESSION IMPACT 174
11.3.2 GERMANY 175
11.3.2.1 Rising number of clinical trials for mAb therapeutics to drive market 175
TABLE 166 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 175
TABLE 167 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 175
TABLE 168 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 176
TABLE 169 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 176
TABLE 170 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 177
11.3.3 UK 177
11.3.3.1 Increasing R&D initiatives by pharmaceutical & biotechnology companies to support market growth 177
TABLE 171 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 177
TABLE 172 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 178
TABLE 173 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 178
TABLE 174 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 178
TABLE 175 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 179
TABLE 176 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 179
11.3.4 FRANCE 180
11.3.4.1 Favorable reimbursement policies for therapeutic treatments to propel market 180
TABLE 177 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 180
TABLE 178 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 180
TABLE 179 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 181
TABLE 180 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 181
TABLE 181 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 182
11.3.5 ITALY 182
11.3.5.1 Growth in life sciences industry to boost demand 182
TABLE 182 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 182
TABLE 183 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 183
TABLE 184 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 183
TABLE 185 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 184
TABLE 186 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 184
11.3.6 SPAIN 185
11.3.6.1 Growing focus on research for biomaterial development to drive market 185
TABLE 187 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 185
TABLE 188 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 185
TABLE 189 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 186
TABLE 190 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 186
TABLE 191 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 187
11.3.7 TURKEY 187
11.3.7.1 Rising investments in R&D for healthcare infrastructure to support market growth 187
TABLE 192 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 188
TABLE 193 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 188
TABLE 194 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 188
TABLE 195 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 189
TABLE 196 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 189
11.3.8 REST OF EUROPE 190
TABLE 197 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 190
TABLE 198 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 190
TABLE 199 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 191
TABLE 200 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 191
TABLE 201 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 192
11.4 ASIA PACIFIC 192
TABLE 202 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 192
TABLE 203 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 193
TABLE 204 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 193
TABLE 205 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 193
TABLE 206 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 194
TABLE 207 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 194
11.4.1 ASIA PACIFIC: RECESSION IMPACT 194
11.4.2 CHINA 195
11.4.2.1 Growing preference for precision medicines to propel market 195
TABLE 208 CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 195
TABLE 209 CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 195
TABLE 210 CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 196
TABLE 211 CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 196
TABLE 212 CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 197
11.4.3 JAPAN 197
11.4.3.1 Availability of healthcare insurance and favorable regulatory environment to propel market 197
TABLE 213 JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 198
TABLE 214 JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 198
TABLE 215 JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 198
TABLE 216 JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 199
TABLE 217 JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 199
11.4.4 INDIA 199
11.4.4.1 Increasing incidence of chronic diseases and high growth in pharma R&D to fuel market 199
TABLE 218 INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 200
TABLE 219 INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 200
TABLE 220 INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 201
TABLE 221 INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 201
TABLE 222 INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 202
11.4.5 SOUTH KOREA 202
11.4.5.1 Strategic initiatives by key players to support market growth 202
TABLE 223 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 203
TABLE 224 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 203
TABLE 225 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 203
TABLE 226 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 204
TABLE 227 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 204
11.4.6 INDONESIA 204
11.4.6.1 Funding initiatives and key product launches to support market growth 204
TABLE 228 INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 205
TABLE 229 INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 205
TABLE 230 INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 206
TABLE 231 INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 206
TABLE 232 INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 207
11.4.7 MALAYSIA 207
11.4.7.1 Increasing focus on government-funded initiatives for management of chronic ailments to support market growth 207
TABLE 233 MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 208
TABLE 234 MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 208
TABLE 235 MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 208
TABLE 236 MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 209
TABLE 237 MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 209
11.4.8 REST OF ASIA PACIFIC 210
TABLE 238 REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 210
TABLE 239 REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 210
TABLE 240 REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 211
TABLE 241 REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 211
TABLE 242 REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 212
11.5 LATIN AMERICA 212
TABLE 243 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 212
TABLE 244 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 213
TABLE 245 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 213
TABLE 246 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 213
TABLE 247 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 214
TABLE 248 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 214
11.5.1 LATIN AMERICA: RECESSION IMPACT 214
11.5.2 BRAZIL 215
11.5.2.1 Increasing incidence of chronic & infectious diseases to drive market 215
TABLE 249 BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 215
TABLE 250 BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 216
TABLE 251 BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 216
TABLE 252 BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 217
TABLE 253 BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 217
11.5.3 REST OF LATIN AMERICA 218
TABLE 254 REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 218
TABLE 255 REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 219
TABLE 256 REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 219
TABLE 257 REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 220
TABLE 258 REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 220
11.6 MIDDLE EAST 220
TABLE 259 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 221
TABLE 260 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 221
TABLE 261 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 222
TABLE 262 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 222
TABLE 263 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 223
TABLE 264 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 223
11.6.1 MIDDLE EAST: RECESSION IMPACT 224
11.6.2 GCC COUNTRIES 224
TABLE 265 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 224
TABLE 266 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 225
TABLE 267 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 225
TABLE 268 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 225
TABLE 269 GCC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 226
TABLE 270 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 226
11.6.2.1 Saudi Arabia 226
11.6.2.1.1 Rising prevalence of CVD to support market growth 226
TABLE 271 SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 227
TABLE 272 SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 227
TABLE 273 SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 227
TABLE 274 SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 228
TABLE 275 SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 228
11.6.2.2 United Arab Emirates 228
11.6.2.2.1 Rising prevalence of diabetes to boost demand 228
TABLE 276 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 229
TABLE 277 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 229
TABLE 278 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 229
TABLE 279 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 230
TABLE 280 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 230
11.6.2.3 Other GCC countries 230
TABLE 281 OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 231
TABLE 282 OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 231
TABLE 283 OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 231
TABLE 284 OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 232
TABLE 285 OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 232
11.6.3 REST OF MIDDLE EAST 233
TABLE 286 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 233
TABLE 287 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 233
TABLE 288 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 234
TABLE 289 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 234
TABLE 290 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 235
11.7 AFRICA 235
11.7.1 HIGH INVESTMENTS IN HEALTHCARE R&D TO SUPPORT MARKET GROWTH 235
TABLE 291 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 235
TABLE 292 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 236
TABLE 293 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 236
TABLE 294 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 237
TABLE 295 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 237
11.7.2 AFRICA: RECESSION IMPACT 237
12 COMPETITIVE LANDSCAPE 238
12.1 INTRODUCTION 238
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 238
FIGURE 34 STRATEGIES ADOPTED BY KEY PLAYERS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET 239
12.3 REVENUE SHARE ANALYSIS 240
FIGURE 35 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2020−2023) 240
12.4 MARKET SHARE ANALYSIS 240
FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023) 241
TABLE 296 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DEGREE OF COMPETITION 241
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 242
12.5.1 STARS 242
12.5.2 EMERGING LEADERS 242
12.5.3 PERVASIVE PLAYERS 243
12.5.4 PARTICIPANTS 243
FIGURE 37 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2023) 243
12.5.5 COMPANY FOOTPRINT 244
FIGURE 38 COMPANY FOOTPRINT (15 COMPANIES) 244
12.5.5.1 Type footprint 245
TABLE 297 TYPE FOOTPRINT (15 COMPANIES) 245
12.5.5.2 Regional footprint 246
TABLE 298 REGIONAL FOOTPRINT (15 COMPANIES) 246
12.6 COMPANY EVALUATION MATRIX: STARTUP/SME PLAYERS 247
12.6.1 PROGRESSIVE COMPANIES 247
12.6.2 DYNAMIC COMPANIES 247
12.6.3 RESPONSIVE COMPANIES 247
12.6.4 STARTING BLOCKS 247
FIGURE 39 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2023) 248
12.7 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 249
TABLE 299 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 249
TABLE 300 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 250
12.8 VALUATION AND FINANCIAL METRICS OF MONOCLONAL ANTIBODY THERAPEUTIC VENDORS 251
FIGURE 40 EV/EBITDA OF KEY VENDORS 251
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 251
12.9 BRAND/PRODUCT COMPARATIVE ANALYSIS 252
12.9.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND SOURCE 252
FIGURE 42 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND SOURCE 252
12.9.1.1 F. Hoffmann-La Roche Ltd. 253
12.9.1.2 Johnson & Johnson Services, Inc. 253
12.9.1.3 Merck & Co., Inc. 253
12.9.1.4 AbbVie inc. 253
12.9.1.5 Sanofi 253
12.9.2 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND HUMAN SOURCE 254
FIGURE 43 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND HUMAN SOURCE 254
12.9.2.1 AstraZeneca 254
12.9.2.2 Bristol Myers Squibb Company 254
12.9.2.3 Novartis AG 255
12.10 COMPETITIVE SCENARIO 255
12.10.1 PRODUCT LAUNCHES & APPROVALS 255
TABLE 301 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2021−JANUARY 2024) 255
12.10.2 DEALS 256
TABLE 302 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DEALS (JANUARY 2021−JANUARY 2024) 256
12.10.3 OTHER DEVELOPMENTS 257
TABLE 303 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: OTHER DEVELOPMENTS (JANUARY 2021−JANUARY 2024) 257
13 COMPANY PROFILES 258
(Business overview, Products/Services offered, Recent developments & MnM View)*
13.1 KEY PLAYERS 258
13.1.1 F. HOFFMANN-LA ROCHE LTD. 258
TABLE 304 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 258
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 259
TABLE 305 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 259
TABLE 306 F. HOFFMAN LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS 263
TABLE 307 F. HOFFMAN LA ROCHE LTD.: DEALS 264
13.1.2 JOHNSON & JOHNSON SERVICES, INC. 266
TABLE 308 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW 266
FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2022) 267
TABLE 309 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS/SERVICES OFFERED 267
TABLE 310 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS 269
13.1.3 MERCK & CO., INC. 272
TABLE 311 MERCK & CO., INC.: COMPANY OVERVIEW 272
FIGURE 46 MERCK & CO., INC COMPANY SNAPSHOT (2022) 273
TABLE 312 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED 274
TABLE 313 MERCK & CO., INC.: PRODUCT APPROVALS 275
13.1.4 ABBVIE INC. 278
TABLE 314 ABBVIE INC.: COMPANY OVERVIEW 278
FIGURE 47 ABBVIE INC.: COMPANY SNAPSHOT (2022) 279
TABLE 315 ABBVIE INC.: PRODUCTS /SERVICES OFFERED 280
TABLE 316 ABBVIE INC.: PRODUCT APPROVALS 280
TABLE 317 ABBVIE INC.: DEALS 281
13.1.5 BRISTOL-MYERS SQUIBB COMPANY 282
TABLE 318 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW 282
FIGURE 48 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2022) 283
TABLE 319 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES OFFERED 284
TABLE 320 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS 285
TABLE 321 BRISTOL-MYERS SQUIBB COMPANY: DEALS 287
TABLE 322 BRISTOL-MYERS SQUIBB COMPANY: OTHER DEVELOPMENTS 287
13.1.6 ASTRAZENECA 288
TABLE 323 ASTRAZENECA: COMPANY OVERVIEW 288
FIGURE 49 ASTRAZENECA: COMPANY SNAPSHOT (2022) 288
TABLE 324 ASTRAZENECA: PRODUCTS/SERVICES OFFERED 289
TABLE 325 ASTRAZENECA: PRODUCT APPROVALS 290
TABLE 326 ASTRAZENECA: DEALS 292
13.1.7 SANOFI 293
TABLE 327 SANOFI: COMPANY OVERVIEW 293
FIGURE 50 SANOFI: COMPANY SNAPSHOT (2022) 294
TABLE 328 SANOFI: PRODUCTS/SERVICES OFFERED 294
TABLE 329 SANOFI: PRODUCT APPROVALS 296
TABLE 330 SANOFI: DEALS 297
13.1.8 NOVARTIS AG 299
TABLE 331 NOVARTIS AG: COMPANY OVERVIEW 299
FIGURE 51 NOVARTIS AG: COMPANY SNAPSHOT (2022) 300
TABLE 332 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 300
TABLE 333 NOVARTIS AG: PRODUCT APPROVALS 302
TABLE 334 NOVARTIS AG: DEALS 303
TABLE 335 NOVARTIS AG: OTHER DEVELOPMENTS 303
13.1.9 AMGEN INC. 304
TABLE 336 AMGEN INC.: COMPANY OVERVIEW 304
FIGURE 52 AMGEN INC.: COMPANY SNAPSHOT (2022) 305
TABLE 337 AMGEN INC.: PRODUCTS/SERVICES OFFERED 306
TABLE 338 AMGEN INC.: PRODUCT APPROVALS 307
TABLE 339 AMGEN INC.: DEALS 308
TABLE 340 AMGEN INC.: EXPANSIONS 308
13.1.10 TAKEDA PHARMACEUTICAL COMPANY LIMITED 309
TABLE 341 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW 309
FIGURE 53 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022) 310
TABLE 342 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS/SERVICES OFFERED 311
TABLE 343 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS 311
13.1.11 GSK PLC. 312
TABLE 344 GSK PLC.: COMPANY OVERVIEW 312
FIGURE 54 GSK PLC.: COMPANY SNAPSHOT (2022) 313
TABLE 345 GSK PLC.: PRODUCTS/SERVICES OFFERED 314
TABLE 346 GSK PLC.: PRODUCT APPROVALS 314
TABLE 347 GSK PLC.: DEALS 315
TABLE 348 GSK PLC.: OTHER DEVELOPMENTS 316
13.1.12 ELI LILLY AND COMPANY 317
TABLE 349 ELI LILLY AND COMPANY: COMPANY OVERVIEW 317
FIGURE 55 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022) 318
TABLE 350 ELI LILLY AND COMPANY: PRODUCTS/SERVICES OFFERED 318
TABLE 351 ELI LILLY AND COMPANY: PRODUCT APPROVALS 320
TABLE 352 ELI LILLY AND COMPANY: DEALS 320
TABLE 353 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS 321
13.1.13 REGENERON PHARMACEUTICALS INC. 322
TABLE 354 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW 322
FIGURE 56 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2022) 322
TABLE 355 REGENERON PHARMACEUTICALS INC.: PRODUCTS/SERVICES OFFERED 323
TABLE 356 REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS 324
TABLE 357 REGENERON PHARMACEUTICALS INC.: DEALS 326
13.1.14 BIOGEN 327
TABLE 358 BIOGEN: COMPANY OVERVIEW 327
FIGURE 57 BIOGEN: COMPANY SNAPSHOT (2022) 328
TABLE 359 BIOGEN: PRODUCTS/SERVICES OFFERED 329
TABLE 360 BIOGEN: PRODUCT APPROVALS 329
TABLE 361 BIOGEN: DEALS 330
13.1.15 UCB S.A. 331
TABLE 362 UCB S.A.: COMPANY OVERVIEW 331
FIGURE 58 UCB S.A.: COMPANY SNAPSHOT (2022) 331
TABLE 363 UCB S.A.: PRODUCTS/SERVICES OFFERED 332
TABLE 364 UCB S.A.: DEALS 332
TABLE 365 UCB S.A.: PRODUCT APPROVALS 333
13.2 OTHER PLAYERS 334
13.2.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 334
13.2.2 Y-MABS THERAPEUTICS, INC. 335
13.2.3 TEVA PHARMACEUTICAL INDUSTRIES LTD. 336
13.2.4 MERCK KGAA 337
13.2.5 KYOWA KIRIN CO., LTD. 338
13.2.6 SWEDISH ORPHAN BIOVITRUM AB 339
13.2.7 UNITED THERAPEUTICS CORPORATION 340
13.2.8 THERATECHNOLOGIES INC. 341
13.2.9 INCYTE 342
13.2.10 SUN PHARMACEUTICAL INDUSTRIES, INC. 342
*Details on Business overview, Products/Services offered, Recent developments & MnM View might not be captured in case of unlisted companies.
14 APPENDIX 343
14.1 DISCUSSION GUIDE 343
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 347
14.3 CUSTOMIZATIONS OPTIONS 349
14.4 RELATED REPORTS 349
14.5 AUTHOR DETAILS 350